On the heels of an already ambitious $100 million expansion plan, Catalent Incorporated has upped the ante by another $100 million. Catalent will invest $100 million in its bulk biological site in Madison, Wisconsin, with the other $100 million going to the Bloomington, Indiana, site. The company bought the 875,000-square-foot Blooomington site last year from Cook Pharmica for $950 million to further expand into biological contract manufacturing.